Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

FEops AI-Enabled Solution Improves Outcomes for Heart Disease Patients

Data from the PREDICT-LAA trial, presented at the Late-Breaking Innovation session at the TCT 2022 convention in Boston shows that Left Atrial Appendage occlusion (LAAO) procedures planned by means of FEops HEARTguideTM result in significantly improved procedural efficiency and outcomes.

The 200 patient PREDICT-LAA prospective, multicenter, randomized controlled trial, led by Dr Ole De Backer (Righshospitalet, Denmark) and Dr Philippe Garot (Institut Cardiovasculaire Paris Sud, France) aimed to assess whether the use of FEops HEARTguidetm computer simulations based on cardiac CT-imaging can contribute to better preprocedural planning and improved procedural outcomes of percutaneous LAAO procedures with the Abbott Amplatzertm Amulettm device.

"PREDICT-LAA is the first-ever clinical study proving that Artificial Intelligence (AI)-enabled computational modelling of device-anatomy interaction significantly improves procedural outcomes. We are proud that we have been able to show that the accuracy of device sizing and positioning for LAAO procedures is significantly better when using FEops HEARTguide as compared to standard CT-sizing", said Prof. Dr. Ole De Backer, Principle Investigator of PREDICT-LAA.

In terms of procedural efficiency, the trial results revealed a doubling of successful single device deployment, a 25% reduction of the use of radiation and contrast medium, a 20% reduction of procedural time and procedural success without major complications in 100% of cases in the FEops HEARTguide arm. Procedural outcomes also significantly improved: 40% more complete LAA occlusion with no leak, 60% less retraction of the Amplatzer Amulet disc into the LAA and 80% reduced risk of device-related thrombus.

"These landmark trial results clearly reinforce the value of our pioneering digital twin strategy to alter the course of heart disease," said Matthieu De Beule, co-founder and CEO of FEops. "We are very proud of the results of the PREDICT-LAA trial and I am very grateful for the visionary drive of all study investigators and the excellent support of Abbott as a funder and the entire FEops team for making this happen to advance how physicians access therapy options for patients at risk of stroke due to atrial fibrillation. The trial results support us in our mission to continue to spearhead AI-enabled digital twin solutions that help treating the right heart disease patients with the right technology at the right time."

About FEops HEARTguidetm

FEops HEARTguideTM cloud-based procedure planning environment uses digital twin technology to provide clinicians and medical device manufacturers with first-ever insights into the interaction between transcatheter structural heart devices and specific patient anatomy ? preoperatively. FEops HEARTguide is available in the USA for use in LAAo with WATCHMANtm, WATCHMANtmFLX, Amplatzer Amuletand in EU, UK, Canada and Australia, FEops HEARTguide is available for use in TAVI and LAAo. FEops HEARTguide has to date been used worldwide for over 6000 patients in over 300 hospitals in over 25 countries. Such insights have the power to improve clinical outcomes in real-world hospital settings, as well as to accelerate research and development of novel device-based solutions.

About FEops

Privately held FEops, headquartered in Gent, Belgium, is a digital health scale-up altering the course of heart disease by providing physicians with unique digital tools to treat the right patients with the right technology at the right time. FEops is supported by Valiance Advisors, Capricorn partners, PMV and the European Innovation Council (EIC) accelerator programme.

FEops contribution to this project was made possible by the funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945698.

Connect with us at www.feops.com or on LinkedIn at www.linkedin.com/company/feops, or contact us via [email protected].

These press releases may also interest you

at 08:00
INT'L DAY OF PEOPLE WITH DISABILITIES: Salesian Missions highlights social and educational programs that promote inclusion Almost 1 billion people living with a disability, according to the World Health Organization. Salesian Missions, the U.S....

2 déc 2022
JelloX Biotech is celebrating a robust year of research and product development milestones while showcasing the potential for 3D imaging and AI to be the future of cancer pathology....

2 déc 2022
AUO Display Plus (ADP) will participate in the...

2 déc 2022
Bright Minds Biosciences Inc. ("Bright Minds" or the "Company") is pleased to announce that, further to its news release on November 28, 2022, it has closed a non-brokered private placement of (i) 666,000 pre-funded warrants of...

2 déc 2022
New Capital Enables Growing Specialty Partnership Organization to Continue to Scale Endodontic Practice Partners (EPP), a Nashville-based specialty partnership organization, announces the securing of an additional debt facility to expand its growing...

2 déc 2022
On December 1, 2022, Mr. Wilmot Matthews acquired 5,555,556 units ("Units") of SQI Diagnostics Inc. ("SQI" or the "issuer") at a price of $0.09 per Unit or an aggregate purchase price of $500,000.04 pursuant to the closing of a non-brokered private...

News published on 17 september 2022 at 10:05 and distributed by: